US20080199425A1 - Sensitization of Immune System Against Haptenized Melanoma Antigens - Google Patents

Sensitization of Immune System Against Haptenized Melanoma Antigens Download PDF

Info

Publication number
US20080199425A1
US20080199425A1 US11/996,753 US99675305A US2008199425A1 US 20080199425 A1 US20080199425 A1 US 20080199425A1 US 99675305 A US99675305 A US 99675305A US 2008199425 A1 US2008199425 A1 US 2008199425A1
Authority
US
United States
Prior art keywords
tyrosinase
cells
compounds
benzenediol
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/996,753
Other languages
English (en)
Inventor
Wiete Westerhof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM (50% PART INTEREST)
ACADEMISCH ZIEKENHUIS LEIDEN (50% PART INTEREST)
Color Stitching Stitching Color
Original Assignee
Color Stitching Stitching Color
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Color Stitching Stitching Color filed Critical Color Stitching Stitching Color
Assigned to COLOR FOUNDATION (STICHTING COLOR) reassignment COLOR FOUNDATION (STICHTING COLOR) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WESTERHOF, WIETE
Publication of US20080199425A1 publication Critical patent/US20080199425A1/en
Assigned to ACADEMISCH ZIEKENHUIS LEIDEN (50% PART INTEREST), ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM (50% PART INTEREST) reassignment ACADEMISCH ZIEKENHUIS LEIDEN (50% PART INTEREST) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLOR FOUNDATION (STICHTING COLOR)
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/996,753 2005-07-28 2005-07-28 Sensitization of Immune System Against Haptenized Melanoma Antigens Abandoned US20080199425A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2005/000551 WO2007013793A1 (fr) 2005-07-28 2005-07-28 Sensibilisation du système immunitaire contre les antigène de mélanome hapténisé

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2005/000551 A-371-Of-International WO2007013793A1 (fr) 2005-07-28 2005-07-28 Sensibilisation du système immunitaire contre les antigène de mélanome hapténisé

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/493,284 Division US9393219B2 (en) 2005-07-28 2012-06-11 Monophenols and benzenediols sensitization of immune system against haptenized melanoma antigens

Publications (1)

Publication Number Publication Date
US20080199425A1 true US20080199425A1 (en) 2008-08-21

Family

ID=36046965

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/996,753 Abandoned US20080199425A1 (en) 2005-07-28 2005-07-28 Sensitization of Immune System Against Haptenized Melanoma Antigens
US13/493,284 Active US9393219B2 (en) 2005-07-28 2012-06-11 Monophenols and benzenediols sensitization of immune system against haptenized melanoma antigens

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/493,284 Active US9393219B2 (en) 2005-07-28 2012-06-11 Monophenols and benzenediols sensitization of immune system against haptenized melanoma antigens

Country Status (9)

Country Link
US (2) US20080199425A1 (fr)
EP (1) EP1909778B1 (fr)
AU (1) AU2005334836B2 (fr)
CA (1) CA2615710C (fr)
DK (1) DK1909778T3 (fr)
ES (1) ES2661169T3 (fr)
HU (1) HUE036189T2 (fr)
SI (1) SI1909778T1 (fr)
WO (1) WO2007013793A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016062265A1 (fr) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 Utilisation du monobenzone pour la préparation d'une composition pharmaceutique indiquée pour le traitement du cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US5702694A (en) * 1993-08-17 1997-12-30 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US20020137961A1 (en) * 2000-09-21 2002-09-26 Pfizer Resorcinol derivatives
US6528051B2 (en) * 1997-11-10 2003-03-04 Cytimmune Sciences, Inc. Methods and compositions for enhancing immune response
US6562363B1 (en) * 1997-09-26 2003-05-13 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2015197C (fr) * 1990-04-23 1999-08-24 Kowichi Jimbow Amide phenolique depigmentante et antimelanome
US5395611A (en) * 1990-04-24 1995-03-07 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
ES2102041T3 (es) * 1992-07-15 1997-07-16 Univ Alberta Tioeter-aminas fenolicas para radioformacion de imagenes y radioquimioterapia y derivados acilados de las mismas para usar en el diagnostico y el tratamiento de trastornos de la pigmentacion.
WO1997001333A1 (fr) * 1995-06-29 1997-01-16 Liliana Leontopol Composition medicamenteuse synergique anticancereuse contenant plusieurs phenols parasubstitues
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
WO2000025763A2 (fr) * 1998-10-30 2000-05-11 Meckel-Spenglersan Gmbh Agents exerçant un effet inhibiteur de proliferation sur des cellules tumorales

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US5702694A (en) * 1993-08-17 1997-12-30 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US6562363B1 (en) * 1997-09-26 2003-05-13 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6528051B2 (en) * 1997-11-10 2003-03-04 Cytimmune Sciences, Inc. Methods and compositions for enhancing immune response
US20020137961A1 (en) * 2000-09-21 2002-09-26 Pfizer Resorcinol derivatives

Also Published As

Publication number Publication date
AU2005334836A1 (en) 2007-02-01
ES2661169T3 (es) 2018-03-27
US20120315304A1 (en) 2012-12-13
CA2615710C (fr) 2017-09-12
HUE036189T2 (hu) 2018-06-28
DK1909778T3 (en) 2018-03-19
EP1909778B1 (fr) 2017-12-13
CA2615710A1 (fr) 2007-02-01
US9393219B2 (en) 2016-07-19
SI1909778T1 (en) 2018-07-31
EP1909778A1 (fr) 2008-04-16
AU2005334836B2 (en) 2012-04-12
WO2007013793A1 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
Westerhof et al. Vitiligo puzzle: the pieces fall in place
Jäger et al. Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo
Seiffert et al. Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells
Toura et al. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide
US8686050B2 (en) Diglycidic ether derivative therapeutics and methods for their use
van den Boorn et al. Monobenzone‐induced depigmentation: From enzymatic blockade to autoimmunity
Naveh et al. Melanoma‐associated leukoderma–immunology in black and white?
Pfarr et al. Simultaneous and dose dependent melanoma cytotoxic and immune stimulatory activity of betulin
Alena et al. Melanocytotoxicity and antimelanoma effects of phenolic amine compounds in mice in vivo
AU665220B2 (en) Method and composition for treating tumors having high tyrosinase activity
Ebrahim et al. Usnic acid benzylidene analogues as potent mechanistic target of rapamycin inhibitors for the control of breast malignancies
US20020001573A1 (en) Immunostimulator anti-cancer compounds
US9393219B2 (en) Monophenols and benzenediols sensitization of immune system against haptenized melanoma antigens
Rusciani et al. Recombinant interferon α-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: A 3-year trial with recombinant interferon-α and 5-year follow-up
US11179385B2 (en) Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
Lee et al. N-(3, 5-dimethylphenyl)-3-methoxybenzamide (A3B5) targets TRP-2 and inhibits melanogenesis and melanoma growth
Ravindranath et al. Role of gangliosides in active immunotherapy with melanoma vaccine
Guillot et al. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth
RU2225206C2 (ru) Лекарственный препарат для профилактики и/или лечения рака молочной железы, содержащий стероидный ингибитор ароматазы
Patsenker et al. 4-O′-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice
Saleh et al. Melanoma immunotherapy: past, present, and future
Kouiavskaia et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer
González et al. Immunological basis of melanoma-associated vitiligo-like depigmentation
Chung et al. Current state of treatment for primary cutaneous melanoma
KR20150027081A (ko) 프테로스틸벤을 사용한 udp-글루쿠로노실 전이 효소 활성 유도 방법

Legal Events

Date Code Title Description
AS Assignment

Owner name: COLOR FOUNDATION (STICHTING COLOR), NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WESTERHOF, WIETE;REEL/FRAME:020413/0285

Effective date: 20080111

AS Assignment

Owner name: ACADEMISCH ZIEKENHUIS LEIDEN (50% PART INTEREST),

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COLOR FOUNDATION (STICHTING COLOR);REEL/FRAME:025234/0069

Effective date: 20101010

Owner name: ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMST

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COLOR FOUNDATION (STICHTING COLOR);REEL/FRAME:025234/0069

Effective date: 20101010

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION